000163588 001__ 163588
000163588 005__ 20240309115309.0
000163588 0247_ $$2doi$$a10.3390/biom12030469
000163588 037__ $$aDZNE-2022-00334
000163588 041__ $$aEnglish
000163588 082__ $$a570
000163588 1001_ $$aBraczynski, Anne K.$$b0
000163588 245__ $$aAlpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo
000163588 260__ $$aBasel$$bMDPI$$c2022
000163588 3367_ $$2DRIVER$$aarticle
000163588 3367_ $$2DataCite$$aOutput Types/Journal article
000163588 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1687189362_9363
000163588 3367_ $$2BibTeX$$aARTICLE
000163588 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163588 3367_ $$00$$2EndNote$$aJournal Article
000163588 520__ $$aParkinson’s disease (PD) is associated with motor and non-motor symptoms and characterized by aggregates of alpha-synuclein (αSyn). Naturally occurring antibodies (nAbs) are part of the innate immune system, produced without prior contact to their specific antigen, and polyreactive. The abundance of nAbs against αSyn is altered in patients with PD. In this work, we biophysically characterized nAbs against αSyn (nAbs-αSyn) and determined their biological effects. nAbs-αSyn were isolated from commercial intravenous immunoglobulins using column affinity purification. Biophysical properties were characterized using a battery of established in vitro assays. Biological effects were characterized in HEK293T cells transiently transfected with fluorescently tagged αSyn. Specific binding of nAbs-αSyn to monomeric αSyn was demonstrated by Dot blot, ELISA, and Surface Plasmon Resonance. nAbs-αSyn did not affect viability of HEK293T cells as reported by Cell Titer Blue and LDH Assays. nAbs-αSyn inhibited fibrillation of αSyn reported by the Thioflavin T aggregation assay. Altered fibril formation was confirmed with atomic force microscopy. In cells transfected with EGFP-tagged αSyn we observed reduced formation of aggresomes, perinuclear accumulations of αSyn aggregates. The results demonstrate that serum of healthy individuals contains nAbs that specifically bind αSyn and inhibit aggregation of αSyn in vitro. The addition of nAbs-αSyn to cultured cells affects intracellular αSyn aggregates. These findings help understanding the role of the innate immune systems for the pathogenesis of PD and suggest that systemic αSyn binding agents could potentially affect neuronal αSyn pathology.
000163588 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000163588 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000163588 650_7 $$2Other$$aParkinson’s disease
000163588 650_7 $$2Other$$aaggregation
000163588 650_7 $$2Other$$aalpha-synuclein
000163588 650_7 $$2Other$$aintravenous immunoglobulins (IVIG)
000163588 650_7 $$2Other$$anaturally occurring antibodies
000163588 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000163588 650_2 $$2MeSH$$aEnzyme-Linked Immunosorbent Assay: methods
000163588 650_2 $$2MeSH$$aHEK293 Cells
000163588 650_2 $$2MeSH$$aHumans
000163588 650_2 $$2MeSH$$aNeurons: metabolism
000163588 650_2 $$2MeSH$$aParkinson Disease: metabolism
000163588 650_2 $$2MeSH$$aalpha-Synuclein: metabolism
000163588 7001_ $$aSevenich, Marc$$b1
000163588 7001_ $$00000-0003-0965-3908$$aGering, Ian$$b2
000163588 7001_ $$00000-0002-5151-6424$$aKupreichyk, Tatsiana$$b3
000163588 7001_ $$aAgerschou, Emil D.$$b4
000163588 7001_ $$aKronimus, Yannick$$b5
000163588 7001_ $$00000-0002-5771-216X$$aHabib, Pardes$$b6
000163588 7001_ $$aStoldt, Matthias$$b7
000163588 7001_ $$00000-0002-0065-7366$$aWillbold, Dieter$$b8
000163588 7001_ $$aSchulz, Jörg B.$$b9
000163588 7001_ $$aBach, Jan-Philipp$$b10
000163588 7001_ $$0P:(DE-2719)2814178$$aFalkenburger, Björn$$b11$$udzne
000163588 7001_ $$aHoyer, Wolfgang$$b12
000163588 770__ $$aSynuclein Proteins
000163588 773__ $$0PERI:(DE-600)2701262-1$$a10.3390/biom12030469$$gVol. 12, no. 3, p. 469 -$$n3$$p469$$tBiomolecules$$v12$$x2218-273X$$y2022
000163588 8564_ $$uhttps://www.mdpi.com/2218-273X/12/3/469
000163588 8564_ $$uhttps://pub.dzne.de/record/163588/files/Braczynski_2022_Biomolecules.pdf$$yOpenAccess
000163588 8564_ $$uhttps://pub.dzne.de/record/163588/files/Braczynski_2022_Biomolecules.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163588 909CO $$ooai:pub.dzne.de:163588$$popenaire$$popen_access$$pdriver$$pdnbdelivery
000163588 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2814178$$aExternal Institute$$b11$$kExtern
000163588 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000163588 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000163588 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-22
000163588 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-22
000163588 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-22
000163588 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-22
000163588 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-22
000163588 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBIOMOLECULES : 2021$$d2022-11-22
000163588 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-07T14:30:28Z
000163588 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-07T14:30:28Z
000163588 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-22
000163588 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-22
000163588 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-22
000163588 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-05-04
000163588 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163588 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-22
000163588 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-22
000163588 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBIOMOLECULES : 2021$$d2022-11-22
000163588 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-22
000163588 915__ $$0StatID:(DE-HGF)10000$$2StatID$$aHosted Content
000163588 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-05-04
000163588 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-22
000163588 920__ $$lyes
000163588 980__ $$ajournal
000163588 980__ $$aI:(DE-2719)1710012
000163588 980__ $$aI:(DE-2719)1040260
000163588 9801_ $$aUNRESTRICTED
000163588 9801_ $$aEXTERN4VITA
000163588 9801_ $$aFullTexts